期刊文献+

10年间3种病理学类型肝癌手术预后变化及其与肿瘤直径和淋巴结转移关系:基于SEER数据库10672例病人长期预后分析 被引量:11

Prognostic changes of three pathological types of hepatocellular carcinoma during the past decade and the relationship with tumor diameter and lymph node metastasis:a long-term prognosis analysis of 10672 patients based on SEER database
原文传递
导出
摘要 目的分析比较肝细胞癌(HCC)、肝内胆管癌(ICC)和混合型肝癌(CHC)病人术后的预后差异。方法回顾性分析SEER数据库2004—2015年间接受手术治疗的原发性肝癌10672例,其中包括HCC病人9044例,ICC病人1421例,CHC病人207例。所有病人包括完整的TNM分期、手术、生存时间及生存状态等信息。比较3种肿瘤术后总体生存(OS)情况及长期预后差异。同时观察N分期亚组(N0组、N1组)及肿瘤直径亚组(0~<2 cm组,2~5 cm组,>5 cm组)中3种肿瘤病人的预后差异,绘制生存曲线并进行多因素cox回归分析校正,进一步行交叉生存曲线Landmark分析。结果自2004—2015年3种病理学类型肝癌病人的3年存活率均有不同程度提高。其中,HCC病人术后总体生存明显优于ICC与CHC。ICC与CHC病人术后的早期预后(<40个月)虽差异无统计学意义,但CHC病人的长期预后(>40个月)显著优于ICC病人(P=0.014)。对影响肿瘤分期的肿瘤直径及淋巴结分期行进一步亚组分析显示,在所有亚组中,HCC病人的预后均优于ICC与CHC,而在N0期亚组以及肿瘤直径<5 cm的亚组中,ICC预后最差;而N1期亚组及肿瘤直径>5 cm的亚组中,CHC预后最差。结论3种病理学类型肝癌病人中,HCC预后最佳,而CHC与ICC在早期(40个月内)虽无预后差异,但CHC的长期预后(40个月以后)明显优于ICC。此外,肿瘤直径>5 cm及N1分期的CHC病人预后差于其他两类肝癌,可能与其具有较强的肿瘤干细胞特性有关。 ObjectiveTo analyze and compare the prognosis of patients with hepatocellular carcinoma(HCC),intrahepatic cholangiocarcinoma(ICC)and combined hepatocellular-cholangiocarcinoma(CHC)after hepatectomy.MethodsThe clinicopathologic data and follow-up results of 9044 patients with HCC,1421 patients with ICC and 207 patients with CHC who underwent liver resection from 2004 to 2015 registered in the American SEER database wereretrospectively analyzed.All these total 10672 patients of primary liver cancer(PLC)had complete information aboutsurgical resection,TNM stage and survival outcomes.The differences of overall survival and long-term survival after resection between 3 types of PLCs were compared.Furthermore,total 10672 patients were divided intosubgroups by N stage and tumor size,and prognosticdifferences between 3 carcinomas were compared foreach subgroup.Kaplan-Meier survival curve andLog-rank test were employed for comparison.Landmark analysis was further performed for crossedsurvival curves.ResultsFor patients undergoingliver resection,3-year survival rates of HCC,ICC and CHC all raised from 2004 to 2015.The overall survival of patients with HCC was significantly better than CHC andICC.What’s more,despite that the prognosis within 40 months were similar between CHC and ICC(P>0.05),the long-term survival after 40 months of CHC was significantly better than ICC(P=0.014).In general,although the survivalbetween CHC and ICC showed no significant difference,ICC had the worst prognosis in N0 subgroup and tumor-size-<5 cm subgroup while CHC had the worst prognosis in N1 subgroup and tumor-size->5 cm subgroup,and HCC showed thebest prognosis in all subgroups.ConclusionFor PLCs patients undergoing liver resection,overall prognosis of HCCwas the best of 3 pathologic types of PLC,and short-term prognosis within 40 months was similar between CHC and ICC.However,long-term survival after 40 months of CHC was significantly better than ICC.Moreover,the surgical outcome ofCHC with tumor size>5 cm and N1 stage was worse than HCC and ICC,which might due to stronger stem cell features.
作者 姚青 张兴 刘昌 曲凯 YAO Qing;ZHANG Xing;LIU Chang;QU Kai(Department of Hepatobiliary Surgery,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
出处 《中国实用外科杂志》 CSCD 北大核心 2020年第11期1308-1313,1319,共7页 Chinese Journal of Practical Surgery
基金 国家自然科学基金项目(No.81773128,No.81871998,No.81972236) 陕西省自然科学基金项目(No.2020JM-373) 中国博士后科学基金(No.2018m641000,No.2019T120921)
关键词 肝细胞癌 肝内胆管癌 混合型肝癌 预后 肿瘤直径 淋巴结转移 hepatocellular carcinoma intrahepatic cholangiocarcinoma combined hepatocellular-cholangiocarcinoma prognosis tumor size lymph node metastasis
  • 相关文献

参考文献4

二级参考文献32

  • 1Xian-Huan Yu,Lei-Bo Xu,Hong Zeng,Rui Zhang,Jie Wang and Chao LiuAuthor Affiliations:Department of Hepato-Pancreato-Biliary Surgery and Department of Pathology,Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University,Guangzhou 510120,China.Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma[J].Hepatobiliary & Pancreatic Diseases International,2011,10(6):620-625. 被引量:7
  • 2Zuo, Huai-Quan,Yan, Lu-Nan,Zeng, Yong,Yang, Jia-Ying,Luo, Hong-Zhi,Liu, Jiang-Wen,Zhou, Li-Xin.Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma[J].Hepatobiliary & Pancreatic Diseases International,2007,6(2):161-165. 被引量:12
  • 3张文宏,翁心华,庄辉.《慢性乙型肝炎防治指南》专家解读[J].中华流行病学杂志,2006,27(6):461-463. 被引量:7
  • 4Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future pros- pects. Semin Liver Dis 2010; 30:61-74.
  • 5Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebou- issou S, Jeannot E, H6rault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J. Transcrip- tome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45:42-52.
  • 6Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, Hosoda F, Imoto I, Inazawa J, Hirohashi S, Shibata T. Geneti- cally distinct and clinically relevant classification of hepato- cellular carcinoma: putative therapeutic targets. Gastroenter- ology 2007; 133:1475-1486.
  • 7Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3:S228-S234.
  • 8Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO clas- sification of tumours of the digestive system. 4th ed. Lyon: IARC, 2010.
  • 9Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen F, Wu MC, Cong WM. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behav- ior. Ann Surg Onco12011; 18:2210-2217.
  • 10Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH, Klimstra D. Combined he- patocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002; 94:2040-2046.

共引文献33

同被引文献100

引证文献11

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部